跳至主要内容
临床试验/NCT02899130
NCT02899130Unknown不适用

Antiviral Effect of 3 Herbs in Chronic Inactive Carriers of Hepatitis B Virus. - A Randomized Placebo Controlled Clinical Trial

Composite Interceptive Med Science1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2016年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
80
试验地点
1
主要终点
Number of patients with change in mean Hepatitis B Virus (HBV) DNA by at least 2log10 units from baseline at end of treatment for those with HBV DNA ≥ 1000 IU/ml.

研究概览

简要总结

This trial will study the effect of a polyherbal capsule in lowering the viral load of patients with chronic Hepatitis B infection and record the incidence of from Hepatitis B surface antigen elimination in 12 months

详细描述

A placebo controlled randomised trial. 3 herbs that have proven effect on eliminating the virus and normalizing liver function will be given. Equally matched placebo (blinded) will be given randomly to patients. All parameters of hepatitis B infection will be compared between the randomized groups

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults aged above 18 years of age, with inactive chronic hepatitis B (HB) or immune tolerant phase, with or without dyslipidaemia and having all of the following
  • HBsAg +ve for >6 months and anti-HBs negative
  • Alanine amino transferase ≤ 2 upper limit of normal
  • HBeAg positive or negative irrespective of viral DNA load
  • Not currently on antiviral therapy for Chronic hepatitis B

排除标准

  • Any one of the following
  • Patients with decompensated liver disease of any etiology(characterized by elevated bilirubin, raised International normalized ratio, or a history of ascites, variceal hemorrhage,hepatic encephalopathy, Spontaneous bacterial peritonitis, hepatorenal syndrome or Hepatocellular carcinoma)
  • Family history of hepatocellular carcinoma
  • Patients with HIV and Hepatitis C virus co-morbidity
  • Pregnant, attempting to conceive, or lactating women
  • Patients with diabetes mellitus
  • Recent history of acute coronary syndrome (<6months) or chronic coronary artery disease with poor left ventricular function (by physician / cardiology opinion)
  • Patients with renal failure ( Creatinine clearance less than 60 ml/min)
  • Active substance or alcohol abuse and concurrent use of corticosteroids or immunosuppressive agents.
  • Presence of extra hepatic manifestations
  • Previously treated with pegylated interferon within the last 2 years
  • Positive fibroscan or ultrasound elastography showing evidence of fibrosis (F3 and above)
  • Current or former employees of organic India
  • Participating in another clinical trial with an active intervention or drug or device with last dose taken within 60 days.
  • Refusing consent or physician uncomfortable with patient compliance to treatments or follow up.

研究组 & 干预措施

Polyherbal

Experimental

Combination of 3 whole herbs in a capsule

干预措施: Polyherbal (Drug)

Matching placebo

Placebo Comparator

Similar looking inert capsules

干预措施: Placebo (Drug)

结局指标

主要结局

Number of patients with change in mean Hepatitis B Virus (HBV) DNA by at least 2log10 units from baseline at end of treatment for those with HBV DNA ≥ 1000 IU/ml.

时间窗: 12 months

次要结局

  • Number of patients with change in hepatitis B surface antigen titers from baseline for those with HBV DNA <1000 IU/ml(12 months)
  • Number of patients with Incidence of seroconversion from Hepatitis B surface antigen to anti-Hepatitis B surface antibody(12 months)

研究者

发起方
Composite Interceptive Med Science
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Effect of Polyherbal Formulation in Chronic Inactive... | 临床试验